[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hiv-seropositivity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hiv-seropositivity":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100494859","hybrid-type-i-effectiveness-implementation-trial-of-a-social-network-support-intervention-100494859",false,"NCT05723653","Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention","Harnessing Social Network Support to Improve Retention in Care and Viral Suppression Among People Living With HIV in Chicago and Alabama: A Hybrid Type I Effectiveness-implementation Trial","Inclusion Criteria for Index Participants:\n\n* Aged 18-49 years old, inclusive\n* Speak English\n* Own a cell phone not shared with anyone else\n* Have missed at least one HIV care scheduled visit or have not been virally suppressed in the past 24 months.\n* Resides in Chicagoland, Illinois or Alabama\n\nExclusion Criteria for Index Men:\n\n* If a participant fails to meet all inclusion criteria\n\nInclusion Criteria for Support Confidants:\n\n* Index agrees to engage the Support Confidant\n* Age 18 years or older\n* Speaks English\n* Owns a cell phone not shared with others\n* Is not a romantic\u002Fsexual partner of the Index participant\n\nExclusion Criteria:\n\n* Romantic\u002FSexual partners of Index participant\n* Relationship strain or abuse present in Index-Support Confidant relationship",true,"ALL","18 Years","49 Years",{"count":21,"type":22},900,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this Hybrid Type I effectiveness-implementation trial is to test an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among people living with HIV aged 18-49.",[28],"HIV Seropositivity",[30,31,32,33],"HIV care engagement","HIV viral suppression","Social support","Social networks","RECRUITING","2026-04-07",{"date":37,"type":38},"2026-04-08","ACTUAL",{"date":40,"type":38},"2023-02-13",{"date":42,"type":22},"2027-12-31",{"name":44,"class":45},"University of Chicago","OTHER",7,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100604208","study-of-the-prevalence-of-transmitted-hiv-1-resistance-viral-diversity-and-cluster-identification-in-patients-at-the-time-of-hiv-1-diagnosis-100604208","NCT07146529","Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis","PRINAVIH","Inclusion Criteria:\n\n* Participant (male or female) aged 18 years or older ;\n* Participant newly diagnosed in the laboratory, for whom mandatory HIV seropositivity reporting to Santé Publique France (SPF) is required ;\n* Participant naïve to all antiretroviral treatments (except PrEP and\u002For post-exposure prophylaxis \\[PEP\\]) ;\n* Participant with an available HIV resistance genotype, including amplification of at least reverse transcriptase and protease ;\n* Participant who has not objected to participating in the study.\n\nExclusion Criteria:\n\n* Participant who objects to the use of their data ;\n* Participant currently on antiretroviral treatment ;\n* Participant subject to legal protection measures (safeguard of justice).",{"count":55,"type":22},30060,"1 Day","OBSERVATIONAL","The primary objective of the study is to determine the frequency of transmission of viruses carrying at least one antiretroviral resistance mutation in all participants newly diagnosed with HIV-1",[28,60,61],"HIV Drug Resistance","HIV Infections",[63,64,65,66,67,68,69],"Genotyping","HIV-1","HIV drug resistance","Transmitted resistance","Viral diversity","Transmission clusters","Primary infection","NOT_YET_RECRUITING","2025-08-21",{"date":73,"type":38},"2025-08-28",{"date":75,"type":22},"2025-09",{"date":77,"type":22},"2036-09",{"name":79,"class":80},"ANRS, Emerging Infectious Diseases","OTHER_GOV",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100514080","immuno-virological-evaluation-of-persons-living-with-hiv-plwh-100514080","NCT05973825","Immuno-virological Evaluation of Persons Living With HIV (PLWH)","Immuno-virological Evaluation of Persons Living With HIV (PLWH) Who Initiated Anti-retroviral Treatment (ART) During Acute HIV Infection and of PLWH on Long Term ART","Inclusion Criteria:\n\nCohort 1: short-term ART cohort\n\n* Documented HIV-1 infection\n* Able and willing to provide written informed consent\n* Age = or \\>18 years and \\\u003C 80 years\n* ART started during a documented recent HIV-1 infection (acute HIV infection, defined as:\n\n  * Clinical symptoms of acute seroconversion and incomplete Western Blot, or\n  * Negative screening test within the past 6 months and incomplete Western Blot, or\n  * Risk contact within the \\\u003C3 months and presumable primo-infection with or without clinical symptoms and incomplete Western Blot.\n* Being on ART since minimum 2 years and maximum 10 years\n* Participants should have had a routine plasma viral load measurement at least once a year.\n* Viral load \\\u003C 40 or \\\u003C50 copies\u002Fml determined by the assay (used in the local centers) for at least 3 years (one blip \\\u003C 200 copies\u002Fml is allowed)\n* Ability and willingness to have blood samples collected and stored for 20 years and used for various research purposes.\n* Patients with HIV-1 subtype B are preferred for inclusion (as most of the complex assays are subtype B specific). However, if the investigators do not reach our target of 10 participants, patients infected with other subtypes will be allowed to enter the study. (Primers will subsequently be adapted to the patient-specific proviral sequences).\n\nCohort 2: long-term ART cohort\n\n* Documented HIV-1 infection\n* Able and willing to provide written informed consent\n* Age = or \\>18 years and \\\u003C 80 years\n* Being on ART since at least 20 years\n* ART should not have been started during a documented recent HIV-1 infection (acute HIV infection), defined as:\n\n  * Clinical symptoms of acute seroconversion and incomplete Western Blot or\n  * Negative screening test within the past 6 months and incomplete Western Blot or\n  * Risk contact within \\\u003C3 months and presumable primo-infection with or without clinical symptoms and incomplete Western Blot.\n* Patients should have had a routine plasma viral load measurement at least once a year.\n* Routine plasma viral load \\\u003C 40 or \\\u003C50 copies\u002Fml determined by the assay used in the local centres for at least 20 years (one blip \\\u003C 200 copies\u002Fml is allowed if it occurred \\>10 years ago)\n* Ability and willingness to have blood samples collected and stored for 20 years and used for various research purposes.\n* Participants with HIV-1 subtype B are preferred for inclusion (as most of the complex assays are subtype B specific). However, if the investigators do not reach our target of 10 participants, patients infected with other subtypes will be allowed to enter the study. (Primers will subsequently be adapted to the patient-specific proviral sequences).\n\nExclusion Criteria:\n\n* Previous or current history of opportunistic infection (AIDS defining events as defined in category C of the Centers for Disease Control and Prevention (CDC) clinical classification), consisting of chronic HIV-1 infection.\n* Evidence of active Hepatitis B-virus (HBV) infection (Hepatitis B surface antigen positive or HBV viral load positive in the past and no evidence of subsequent seroconversion (= HBV antigen or viral load negative and positive HBV surface antibody).\n* Evidence of active HCV infection (HCV antibody positive result within 60 days prior to study entry with positive HCV viral load or, if the HCV antibody result is negative, a positive HCV RNA result within 60 days prior to study entry).\n* Current or known history of cardiomyopathy or significant ischemic or cerebrovascular disease.\n* Current cancer.\n* History of HIV-related thrombocytopenia.\n* Pregnancy or breastfeeding.\n* Any condition, including preexisting psychiatric and psychological disorders, which will in the opinion of the investigator interfere with the trial conduct or safety of the participant.\n* Abnormal results of standard of care laboratory tests:\n\n  1. Confirmed haemoglobin \\\u003C11g\u002Fdl for women and \\\u003C12 g\u002Fdl for men\n  2. Confirmed platelet count \\\u003C100 000\u002Fµl \\*\n  3. Confirmed neutrophil count \\\u003C1000\u002Fμl\n  4. Confirmed Aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT)\\>10x upper limit of normal (ULN)\n* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.\n* Acute or serious illness, in the opinion of the site investigator, requiring systemic treatment and\u002For hospitalization within 60 days prior to entry.","80 Years",{"count":90,"type":22},24,[25],"This is a dual arm (arm 1 and arm 2) multi-centric non-randomized (prospective) study.\n\nTwo new multicentric cohorts will be set up in 4 Belgian HIV reference centers (UZ Gent, UZ Brussel, University Hospital Liege and St. Pierre Hospital Brussels): cohort 1 will comprise PLWH in whom ART was initiated during acute HIV infection minimum 3 years ago but no more than 10 years ago (short-term ART cohort); cohort 2 will comprise PLWH on ART since \\>20 years (long-term ART cohort). Participants will be included based on suppressed viremia and uninterrupted ART since initiation. Participants will undergo one blood sampling and one leukapheresis. In and exclusion criteria are described below.",[94,28],"HIV-1-infection","2024-07-12",{"date":97,"type":38},"2024-07-15",{"date":99,"type":22},"2024-09-01",{"date":101,"type":22},"2029-07-12",{"name":103,"class":45},"University Hospital, Ghent",1]